Phase 3 N=7 A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)
Alagille Syndrome (ALGS)
Primary: Change in Fasting Serum Bile Acid (sBA) Levels From Week 18 to Week 22 — 17.643 micromoles per liter (mcmol/L)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=7,526 An Evaluation of Virtual Psychiatric Transition of Care Offered in Behavioral Health
Mental Health Issue
Primary: Number of Participants With All Cause Non-elective Acute Care Post Discharge Utilization Within 30 Days — 941; 973 Participants — p=<0.001
Phase 2 N=25 A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma
Asthma
Primary: Safety: Relative Change From Baseline* in Forced Expiratory Volume in 1 s (FEV1) -- 15 Min Post-dose — 2.12; 0.26 percent change — p=0.113
Phase 2 N=62 A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Overall Survival — 8.6; 4.7 months
N/A N=120 Shared Decision Making in Rural Primary Care Lung Cancer Screening and Smoking Cessation
Lung Cancer · Smoking Cessation
Primary: Count of Participants Who's Health Visit Adhered to the LCS Guidelines and CMS Coverage Criteria in Rural Primary Care Practices: Baseline Survey — 0; 0 participants
Phase 1 N=16 Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor®) for Atrophic Vaginitis in Breast Cancer Patients
Atrophic Vaginitis
Primary: Serum Concentrations of Estriol (E3) — 0; 0.91; 3.83; 1.58 pg/ml
N/A N=10,117 All-Case Surveillance of Ofev in Patients With IPF in Japan
Idiopathic Pulmonary Fibrosis
Primary: Number of Patients With Any Suspected Adverse Drug Reactions (ADRs) — 3852 Participants
Phase 1 N=34 A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women
Vulvovaginal Atrophy · Vasomotor Symptoms
Primary: To Determine the Steady State Concentration (Css) for Estradiol — 14.4; 29.7; 33.8 pg/mL
Phase 2 N=46 Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
Liver Cancer
Primary: Number of Participants With Complete Response or Partial Response (Objective Response), as Assessed According Central Review — 22; 22 Participants
Phase 2 N=72 CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery
Prescription Opiate/Medication Dependence
Primary: Illicit-positive Urines During Treatment and Follow-up — 0; 0; 1; 1 Participants
N/A N=13 Initial Clinical Experience With the MONARCH Platform, Urology for the Treatment of Kidney Stones
Kidney Calculi
Primary: Completion of the Robotic Assisted Mini-PCNL Kidney Stone Removal Procedure. — 12 Participants
N/A N=35 Evaluation of Satisfaction Regarding Home Healthcare Provider (HHP) Management of Type 1 Diabetic Patients Using a Closed-loop Automatic Insulin Delivery System
Diabetes type1
Primary: Number of Participants With Satisfaction Regarding the Management in General, at Day 30 and Day 90, by the CSQ-8 Questionnaire — 35; 35 Participants
Phase 2 N=16 Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
Non Alcoholic Steatohepatitis
Primary: NAS Score (Nonalcoholic Fatty Liver Disease [NAFLD] Activity Score) — -1.50; -1.86; -1.33 units on a scale — p=0.7689
Phase 1 N=32 A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number ot Participants With Treatment Emergent Adverse Events — 2; 2; 2; 1 participants
Phase 3 N=7,769 Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
HIV · Cardiovascular Diseases
Primary: Incidence Rate of Major Adverse Cardiovascular Event (MACE) — 4.95; 7.77 events per 1000 person-years